公司基本信息

广州因答生物技术有限公司

所属行业：	医药/生物工程+医疗设备/器械,医疗/护理/美容/保健/卫生服务
公司性质：	合资
公司规模：	20人以下
公司地址：	广州国际生物岛螺旋四路2栋307-308
公司介绍：	因答生物科技有限公司（简称：因答生物），是由中组部千人计划特聘教授、美国莫菲特癌症中心医学主任、全球药物基因组学倡议组织（PGENI）主席Howard L. McLeod教授及项目核心团队成员2016年12月在深圳大鹏新区成立的肿瘤精准诊疗的高新技术企业。主营业务为以肿瘤免疫治疗伴随诊断为核心的肿瘤精准医学检测服务及相关体外诊断试剂的研制与生产。公司拥有高通量二代测序技术，流式细胞仪检测外周血T细胞活力技术、CTC免疫荧光技术、细胞免疫因子检测技术、PD-L1免疫组化检测技术以及人工智能辅助诊断系统（CiDex）。通过实验室检测技术与辅助诊断系统结合，我们能够对肿瘤免疫治疗疗效，预后评估进行综合伴随诊断，并给予临床合理的用药建议。其中全球独家的流式细胞仪T细胞活力检测技术由美国墨菲特癌症中心独家授权使用。公司管理团队由具有丰富行业经验的专业人员担任。公司目前已与中山大学肿瘤医院、中南大学湘雅医学院、哈尔滨工业大学、湖南省肿瘤医院、深圳市人民医院等中国著名的大学和医疗机构形成了战略伙伴关系，在产品临床试验、联合研发、品牌推广、人才培训、信息共享等多方面展开深度的战略合作。公司与深圳罗兹曼国际转化医学研究院在肿瘤免疫治疗药物新药开发及伴随诊断方面展开深度科研及产业化合作，打通从新药研发到药物伴随诊断上下游产业链，形成协同创新体系。公司成立后获得了勤智资本、红杉资本、越秀产投和中大创投等多家国内外知名投资机构的认可，为公司今后发展打下了良好的基础。目前成立了全资子公司广州因答生物技术有限公司，进驻广州国际生物岛。 Guangzhou INDA Biotechnology Co., Ltd., was founded in Dapeng new district of Shenzhen in December, 2016. It is an innovative high-tech enterprise specializing in the precision medicine of oncology. The founders of INDA consists of several experts from USA leading by Prof. Howard L. McLeod who is a 1000 talent scholar awarded by the Recruitment Program of Global Experts, the medical director of Moffitt cancer center and the chair of PGENI (Pharmacogenetics for Every Nation Initiative). INDA focuses on the testing service of precision medicine in oncology and developing and manufacturing of related in vitro diagnostic reagents (IVD), especially companion diagnostics of cancer immunotherapy. Our Company can perform companion diagnostic tests for cancer immunotherapy multidimensionally including high-throughput sequencing technology for TMB/MSI test, flow cytometry for analyzing the activity of T cells in circulation, tests on circulation tumor cells (CTC) by immunofluorescence, cytokine detection by ELISA, and immunohistochemical (IHC) staining for PD-L1 expression. We have also developed an artificial intelligent auxiliary diagnosis system, CiDex, to help medical oncologists make smarter decisions during clinical practice. The flow cytometry assay is a patented technology with exclusive authorization from Moffitt Cancer Center & Research Institute, USA. INDA has established strategic partnerships with many prominent Chinese universities and medical institutions such as Sun Yat-sen University Cancer Center, Xiangya School of Medicine of Central South University, Harbin Institute of Technology, Hunan Cancer Hospital, Shenzhen People’s Hospital. We collaborate deeply in the areas of clinic trials, joint R&D, brand promotion, personnel training and information sharing. We have also established a strong collaboration with the Shenzhen International Institute for Biomedical Research (SIIBR) in the field of cancer immnuotherapy related drug development and companion diagnostics, aiming to establish an industrial chain of drug development and companion diagnostics. INDA has gained recognition from the well-known investment communities including Triwise Capital, Sequoia Capital, Yuexiu Industrial Fund and Zhongda Venture Capital, laying the foundation for future financing and development. The Company received first-round venture financing in September 2017, led by Triwise Capital, followed by China’s pharmaceutical industry listed companies.

广州因答生物技术有限公司热招职位(0)

招聘职位

年薪范围

工作地点

广州因答生物技术有限公司页面介绍

【智联卓聘网】为您提供最新广州因答生物技术有限公司介绍，包括公司地址，最新招聘信息等。

广州正在招聘的公司推荐

其他公司推荐